Development of the IMD

It shows that domestic pharmaceutical companies are focusing on Development of the Incrementally Modified Drug (IMD) such as Controlled Release Drug and Compound drug.

KFDA reported that total 757 drugs including 6 items of new drugs and 1 IMD were permitted in Korea for sales during last 2months, from March to April.

Specifying them, total 367 items of complete drug were acquired sales permit from KFDA, 301 items were ETC drug (including 6 orphan drugs), 66 items were OTC drugs. And also 268 medicinal herbs and 122 bulk medicines were permitted.

Analysts believe that as it is not easy to develop innovative new substance in our pharmaceutical environment, development of the IMD such as Controlled Release Drug and Compound drug are increasing to take benefit from study period and cost.

CLAZA CR (Aceclofenac: Korea united pharmaceutical company), a pain releasing agent for RA, OA and etc, categorized into NSAIDs, were certificated its efficacy and advance through modifying its administration and dosage from BID to OD with improvement of dosage form.

Also Compound drugs which combined proven components are being developed, especially, counseling related to dyslipidemia and anticoagulants complex development are increasing lately.

KRDA explained that “As society is aging and market growth of those chronic disease related to aging population is expected, makes domestic pharmaceutical companies concentrate on developing those kind of drugs.”

Also rapid increase of anti-HBV agents permission is the one of the remarkable phenomenon on April.

Especially, since the period of HEPCERA 10mg (Adefovir dipivoxil: GSK) review has been expired on February, 34 generics were permitted on last April.

KFDA expected that “Those generics permission from KFDA through proving bioequivalence with original drug will offer a more wide treatment choice to HBV patients.”

Source:http://eng.kpanet.or.kr/bbs/desc.jsp?cat=eng_news&oid=13824&pg=0